Pain Market Landscape and

Assessment
Market Analysis and Research Proposal

January 2016

0
 Content

• Background and Objectives

• Approach and Methodology
• Project Team
• Timeline and Investment

1 IMS Health Confidential

 Within multinational players, antineoplastic still shows its dominance
whilst analgesics exists in more crowded market with lower growth
MAT Growth Sales (Bio IDR) and growth (%) of top therapeutic areas2 in Indonesia
65
Emerging 100 Sustainable
60 L01-ANTINEOPLASTICS

55

L02-CYTOSTATIC HORMONE THERAP

50
CAGR 5Y = 47.1%
MAT = 98.1%
45
K01-INTRAVENOUS SOLUTIONS
40

35
N03-ANTI-EPILEPTICS
30
R03-ANTI-ASTHMA & COPD PROD
A02-A-ACID A-FLAT A-ULCERANTS
25
C09-RENIN-ANGIOTEN SYST AGENT A10-DRUGS USED IN DIABETES
20
N05-PSYCHOLEPTICS N02-ANALGESICS MAT Growth Market = 20.0%
15
C08-CALCIUM ANTAGONISTS

10 G04-UROLOGICALS
N01-ANAESTHETICS
5 M01-ANTIRHEUMATIC SYSTEM
B01-ANTITHROMBOTIC AGENTS J07-VACCINES 50
0
-5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
-5 G03-SEX HORMONES CAGR
J01-SYSTEMIC ANTIBACTERIALS
C10-LIPID-REG/ANTI-ATHEROMA
-10
R06-ANTIHISTAMINES SYSTEMIC
Stagnant Decelerating
-15
CAGR 5Y Market = 13.2% 45
Source : ITMA Ethical Only Multinational Company

2 IMS Health Confidential

 Although it is existed in stagnant market, analgesics itself is a fragmented
category as its sub-categories performs and functions differently
Sales (Bio IDR) and growth (%) of top therapeutic areas2 in Indonesia
40
Emerging Sustainable

35

N02A-NARCOTIC ANALGESICS, 115

MAT Growth

30

25

N02C-ANTI-MIGRAINE PREPS, 17
20

15

10
N02B-NON-NARCOTIC MAT Growth Market = 10.9%
ANALGESICS, 1,343

Stagnant CAGR 5Y Market = 12.4%

Decelerating
CAGR
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
45
45
Source : ITMA Ethical Only
3 IMS Health Confidential
 In relation with analgesic market, WHO has formulated a structured ‘pain
management ladder’

MILD PAIN MODERATE PAIN SEVERE PAIN

Persistent

Persistent
First • Strong Opioid
presentation • +/- Non Opioid
• +/- Adjuvant
• Mild Opioid
• +/- Non Opioid
• Non-Opioid • +/- Adjuvant
• +/- Adjuvant
Pain management/analgesic ladder recommends skipping to step (2) or (3) if the 1st presentation is moderate or severe pain
respectively ~ IMS internal study

4 IMS Health Confidential

 Pain management is a broad and dynamic therapy area. It is important to
understand it from the fundamental point of view
Global ‘pain management’ market is estimated to grow at a strong pace of +10% CAGR
annually*

Global ‘pain management’ pharmaceutical market is

estimated to be around ~US$30billion*

It is projected to grow at a strong pace of +10% CAGR

annually*

NSAIDs, COXIBs, Mild analgesics and Opioids are some of

the pharmaceutical choices to combat different severities of
pain

 Orthopedic surgeries are generally considered as the most painful surgeries, because they involved
extremities bones & nerves. The use of opioid analgesics in post surgery in Indonesia is still very
minimal, especially compared to developed countries (even still very low compared to other Asian
countries).
 In Indonesia, almost all specialties treat pain patients. Among the specialties, anesthesiologists,
neurologists and orthopedic surgeons are the most productive in prescribing analgesics
*Source – Secondary research IMS Regional
5 IMS Health Confidential
 There are several key objectives to be achieved in order for
Mundipharma to successfully launch opioid drugs in analgesic sector..
• To understand pain market landscape and competition dynamic –
narcotic and non narcotic analgesic
Understanding pain • To provide an overview of BPJS regulatory and procurement policy
management market – impacting the pain market , related insights focus on narcotic
Pain portfolio segment
assessment • To assess related drugs in the treatment of moderate to severe pain
within narcotic and non-narcotic segment , which has high potential in
Indonesia
• To define pain management in general, but deeper evaluation of
Identifying opioid moderate to severe pain , from HCPs and competitors point of view
market size against • To identify market size of pain market, especially for opioid category
other molecules, (against other molecules) i.e. oxycodone to be précised
segment and • To understand competitive environment, market’s major players and
opportunity leading brands from physicians, competitors and channels point of
view
• To understand the usage and attitude towards opioid drugs and
treatment options
• To explore driver and barriers in using opioid drugs
Exploration on • To identify diagnosis and treatment process amongst patients with
demand initiation in opioid drugs
opioid drugs • To explore key influencers on HCPs when prescribing pain drugs for
patients
• To understand the acceptance on Mundipharma’s drugs : Oxynorm,
Oxyneo and Targin
6
 .. and key areas that IMS will concentrate on as below, to support
Mundipharma in understanding the opioid market in Indonesia :

• To define pain management in general, but deeper evaluation of

Identifying opioid moderate to severe pain , from HCPs and competitors point of view
market size against • To identify market size of pain market, especially for opioid category
other molecules, (against other molecules) i.e. oxycodone to be précised
segment and • To understand competitive environment, market’s major players and
opportunity leading brands from physicians, competitors and channels point of
view
• To understand the usage and attitude towards opioid drugs and
treatment options
• To explore driver and barriers in using opioid drugs
Exploration on • To identify diagnosis and treatment process amongst patients with
demand initiation in opioid drugs
opioid drugs • To explore key influencers on HCPs when prescribing pain drugs for
patients
• To understand the acceptance on Mundipharma’s drugs : Oxynorm,
Oxyneo and Targin

7
 Content

• Background and Objectives

• Approach and Methodology
• Project Team
• Timeline and Investment

8 IMS Health Confidential

 We recommend a two-phased approach to achieve key objectives of
study we have set forth
Stage 1 Stage 2
1 2
Market Sizing Study Synthesis Usage and Attitude
Way Forward
– Identifying
Discussion and
Workshop
study – Opioid Workshop
opportunity Prescription
Behaviour

1a Definition of pain 2a
Opioid prescription
management and
behaviour and
potential pain class
treatment pathway
of drugs

1b 2b
Identifying drivers
Market sizing (value, and barriers in
volume and growth) prescribing drugs

1c 2c
Competition
environment in Pain Drug Concept
moderate to severe Evaluation
pain drugs therapy

9
 IMS uses a strong research methodology to support Mundipharma
examine and understand pain market performance in Indonesia
IMS PANEL DATA
• 500 pharmacy & drug store
panel from IMS audit data
• 1000 doctor panel from IMDI
data
IMS will utilize proprietary
data to provide insights as well
as set the criteria of
respondent for Primary
Research
10
PRIMARY RESEARCH
KOLs Competitors
Phone Interview
• Phone Interview will be used as brief yet exclusive
discussion. Phone interview will be more effective due
to information confidentiality, complexity and details
• The exploratory study will be conducted
exclusively with competitors in order to understand
market competition and dynamic
Focus Group Discussion
• Mini FGD will be used to get exclusivity and
intensive discussion, group consensus and topic
stimulation at the same time.
• Qualitative discussion with KOLs is used to
gather detail attributes on brand attitude and
behavior and brand equity performance which will
be used later in Demand Initiation stage
 Study Approach
Stage 1 Stage 2
1 2
Market Sizing Study Synthesis Usage and Attitude
Way Forward
– Identifying
Discussion and
Workshop
study – Opioid Workshop
opportunity Prescription
Behaviour

1a Definition of pain 2a
Opioid prescription
management and
behaviour and
potential pain class
treatment pathway
of drugs

1b 2b
Identifying drivers
Market sizing (value, and barriers in
volume and growth) prescribing drugs

1c 2c
Competition
environment in Pain Drug Concept
moderate to severe Evaluation
pain drugs therapy

11

Market sizing study will be done through several stages*
1a
Definition of pain
management and
potential pain class of
drugs
Key Activities
• Gather information from
related KOLs across specialists
in pain category, especially
moderate to severe pain area
Benefits
• Identifying the definition of pain
management as general, and
moderate to severe pain as
specific
• Exploring ideal treatment for
moderate to severe pain from
HCPs point of view
• Understanding pain definition,
specialties engaged in pain
treatment and palliative care
role in pain management in
Indonesia compared with
advanced countries
12 * = The study will be conducted in sequels in order to gather relevant and to conduct solid analysis
1b
Market sizing (value,
volume and growth)
• Gather relevant, available data
from IMS database analysis
• Understanding market size of pain
market, especially moderate to
severe pain, according to HCPs
definition and specialties related
• Understanding market size of pain
market, according to IMS
definition (from ITMA and IMDI
database)
• Identifying the gap between HCPs
and IMS definition (if there is any),
in terms of definition, value,
volume and growth
Stage1-Market Sizing Study
1c
Competition
environment in
moderate to severe
pain drugs therapy
• Gather relevant, available data
from IMS database analysis
• Gather competition dynamic
from relevant and potential
competitors
• Understanding competition trend
and overview on moderate and
severe pain drugs
• Understanding competitive
environment, the market’s major
players and leading brands from
competitors point of view
 Market Sizing Study – Phase 1A
Phase 1a aims to identify the definition of pain management according to
respective HCPs point of view
1a 1b 1c
Definition of pain Competition
management and Market sizing (value, environment in
potential pain class of volume and growth) moderate to severe
drugs pain drugs therapy

Key activities Deliverables

• Gather information from related 1. Definition of pain management for moderate to severe pain
KOLs across specialists in pain 2. Specialties and pain management treatment related – identify the role of
category, especially on moderate palliative care in pain management
to severe pain management 3. Comparison of pain management treatment between advanced vs
developing countries (drugs used, diagnostic tools used, specialists
• Mini Focus Group Discussions involved, home care vs hospital care treatment)
(FGD) with KOLs from respective
4. Ideal treatment of mild to severe pain and considerations
specialists :
• Anesthetics, Neurologist,
Orthopedic, Oncologist and
Internist

13
 Market Sizing Study – Phase 1A
Mini FGDs with KOLs
Qualitative Methodology
• This will be done through Mini FGD with KOLs across related specialties. Each group consists of 2-
3 KOLs.

• Mini FGD is used to get both detail findings, supported by idea stimulation and group consensus at
the same time. In the session, we will understand the overall perception and expectation towards
mild to severe pain management, understanding the ideal treatment and the dynamic within the
narcotic analgesic category.

• The session also will help us to get detail findings on their experience in taking care of
moderate to severe pain through group sharing session.

• This will be done through effective session around 90mins.

• A Trained Moderator, specialized in pharmaceutical industry, shall conduct the discussions

• A Discussion Guide, in the form of a open ended questionnaire (supported by few close-ended
questionnaire) , will be used to ensure that all pertinent topics are covered

14 IMS Health Confidential

 Market Sizing Study – Phase 1A
Mini FGDs with KOLs – cont’d
Sample Composition and Criteria
• Has experience as a HCPs/specialist at least 8years and have depth knowledge on
pain management
• Have experience in being key note speaker in advanced wound seminar/RTD
KOLs • Have experience as consultant for related association
• Open practice in public / private hospitals
• Mix of specialist related :
• Anesthetic
• Oncologist
• Neurologist
• Internist
• Orthopedic Surgeon
• Have experience in handling cancer pain / post-operation pain
• Open practice in Jakarta
City Anesthetic Oncologist Neurologist Internist Orthopedic
Surgeon

JKT 1 1 1 1 1

TOTAL (N) 5

No.of Sample for KOLs : 5 Mini FGDs (To be discussed with Mundipharma on number of groups to be
conducted by IMS versus Mundipharma internally)

15 IMS Health Confidential


Phase 1b aims to identify the definition of pain management according to
respective HCPs point of view
1a
Definition of pain
management and
potential pain class of
drugs
Key activities
• Gather relevant, available data
from IMS database analysis –
combination of ITMA and IMDI
data on respective TCs
16
Market Sizing Study – Phase 1B
1b 1c
Competition
Market sizing (value, environment in
volume and growth) moderate to severe
pain drugs therapy
Deliverables
1. Market size is defined by [each level of pain]:
o Annual Sales volume, Annual Unit volume, Market Growth
2. Patients case load (number of patients, HCPs productivity), patients
profile, patients medical profile, prescription trend (by specialist and by
brand), diagnosis share, brand share – based on prescription)
3. Market size and dynamics according to HCPs definition – identify the
gap
 Market Sizing Study – Phase 1C
Phase 1c aims to identify the definition of pain management according to
respective HCPs point of view
1a 1b 1c
Definition of pain Competition
management and Market sizing (value, environment in
potential pain class of volume and growth) moderate to severe
drugs pain drugs therapy

Key activities Deliverables

• Gather relevant, available data 1. Market dynamics and environment [each level of pain] :
from IMS database analysis o Key and leading players, market trend from time to time
• Gather competition dynamic from 2. Obstacles, challenges and dynamics – market entry and competition
relevant and potential competitors 3. Distribution flow and challenges – role of each channel, key influential
• To acquire market and potential channels and reasons
information from relevant and
potential competitors
• Phone interviews with
current key players (such as
Kimia Farma and Janssen)
to gather brief and additional
information on industry
dynamic and challenges

17
 Market Sizing Study – Phase 1C
Phone Interviews with competitors
Qualitative Methodology
• Phone interview is used to gather brief information on certain issues, such as market dynamic an
competition on pain market, especially opioid drugs through relax and exclusive session.

• This is to get indication findings on competition based on their experience as market

practitioner in pain market particularly moderate to severe pain.

• This will be done through effective session around 15-20mins.

• A Trained Moderator, specialized in pharmaceutical industry, shall conduct the discussions

• A Discussion Guide, in the form of a open ended questionnaire will be used to ensure that all
pertinent topics are covered

Sample Criteria

• Has experience as a Brand/Product manager at least 4years in related category and have depth
knowledge on pain management
• Working at respective company for at least 2 years
• Total sample, N=2

18 IMS Health Confidential

 Summary on samples and methodology in Stage 1
1a Definition of pain
City Mini FGDs with KOLs

management and JKT 5

potential pain class of
drugs General criteria :
• Has experience as a HCPs/specialist at least 8years and have depth knowledge
on pain management
• Have experience in being key note speaker in advanced wound seminar/RTD
• Have experience as consultant for related association
• Open practice in public / private hospitals

1b Source of Data

Market sizing (value, ITMA – Ethical

volume and growth)
IMDI data within related categories

1c Source of Data
Competition
environment in ITMA – Ethical
moderate to severe
pain drugs therapy City Phone Interviews

JKT 2

General criteria :
• Has experience as a Brand/Product manager at least 4years in related category
and have depth knowledge on pain management
• Working at respective company for at least 2 years

19 IMS Health Confidential

 Study Approach
Stage 1 Stage 2
1 2
Market Sizing Study Synthesis Usage and Attitude
Way Forward
– Identifying
Discussion and
Workshop
study – Opioid Workshop
opportunity Prescription
Behaviour

1a Definition of pain 2a
Opioid prescription
management and
behaviour and
potential pain class
treatment pathway
of drugs

1b 2b
Identifying drivers
Market sizing (value, and barriers in
volume and growth) prescribing drugs

1c 2c
Competition
environment in Pain Drug Concept
moderate to severe Evaluation
pain drugs therapy

20
 Stage2-Usage & Attitude Study
Usage and Attitude (U&A) study will be done through several stages
2a 2b 2c
Opioid prescription Identifying drivers and
Pain Drug Concept
behaviour and barriers in prescribing
Evaluation
treatment pathway drugs

Key Activities
• Gather information from HCPs across specialists through Face-to-face interview to understand prescription behaviour in
treating moderate and severe pain. This method will uncover the category and behaviour understanding through statistical robust
definitive which can help Mundipharma in making decisions for business and marketing strategy.

Benefits
• Understanding treatment • Identifying drivers and barriers in • Understanding HCPs level of
journey for severe and pain prescribing the drugs, and acceptance towards new product
management across specialists reasons of pain drug from Mundipharma
– molecules and brands used in • Identifying key influencers • Identifying points to be improved
each line treatment amongst HCPs in prescribing pain in the product concept in order to
• Understanding HCPs drugs form a launching strategy more
perception and behaviour effectively
towards pain drugs in treating
• Identifying HCP’s level of future
moderate and severe pain
intention in using the new pain
management
drug stated in the concept
• Identifying attributes in
prescribing the drugs –
consideration factors from most
to least important
21
 Methodology and Deliverables

22
 Stage2-Usage & Attitude Study
Research Methodology
Quantitative Methodology

• IMS approach is to used quantitative methodology at this stage in order to get a more robust data in
understanding HCPs usage and attitude towards pain drugs category, as well as HCPs acceptance
level on the new pain drug concept offered. This approach will be done through Face-to-Face
interview with HCPs across specialties

• This will be done through session around 45mins.

• A Trained Interviewer, specialized in pharmaceutical industry, shall conduct the discussions

• A Questionnaire, in the form of a semi-close ended questionnaire (supported by few open-ended

questionnaire) , will be used to ensure that all pertinent topics are covered
• Some attributes will be collected from the findings at first stage (Mini FGDs with KOLs)

23
 Stage2-Usage & Attitude Study
Sample Composition and Criteria
Criteria and Number of Sample
• Has experience as a specialist at least 3 years and have experience in handling
moderate to severe pain management
• Open practice in public / private hospitals
HCPs • Mix of specialist related :
• Anesthetic
• Oncologist
• Neurologist
• Internist
• Orthopedic Surgeon
• Have experience in handling cancer pain / post-operation pain
• Open practice in Jakarta

City Anesthetic Oncologist Neurologist Internist Orthopedic

Surgeon

JKT & SBY 30 30 30 30 30

TOTAL (N) 150

(Sample composition is to be further discussed with Mundipharma)

24
 Stage2-Usage & Attitude Study
Key Informational Coverage and Sample Deliverable
2a 2b 2c
Opioid prescription Identifying drivers and
Pain Drug Concept
behaviour and barriers in prescribing
Evaluation
treatment pathway drugs

Key Informational Sample Deliverables

• Patients profile per specialist : Total
patients, % of moderate vs severe, % of
referred vs direct patients, % of new vs
repeat patients, % of in-patient and out-
patient
• Treatment behaviour for each moderate
and severe level of pain :
• 1st line treatment, 2nd line treatment etc –
molecules and drugs/brands prescribed,
and reasons, dosage, length of treatment,
drugs switching behaviour, mono vs multi-
drugs therapy behaviour
• Symptoms related to the prescribed drugs
• Tools used for diagnosis

25 IMS Health Confidential

 Stage2-Usage & Attitude Study
Key Informational Coverage and Sample Deliverable
2a 2b 2c
Opioid prescription Identifying drivers and
Pain Drug Concept
behaviour and barriers in prescribing
Evaluation
treatment pathway drugs

Key Informational Sample Deliverables

• Drivers attributes/ considerations in
prescription : Price, efficacy, safety,
patients or patient preference
• Brands performance/ association on related
attributes
• Challenges/ barriers in treating pain –
moderate vs severe
• Influencers in prescribing pain drugs –
company’s promotion activities/ events,
scientific approach
• Expectation on pain treatment – type of
drugs related, composition, dosage, length
of treatment

26 IMS Health Confidential

 Stage2-Usage & Attitude Study
Key Informational Coverage and Sample Deliverable
2a 2b 2c
Opioid prescription Identifying drivers and
Pain Drug Concept
behaviour and barriers in prescribing
Evaluation
treatment pathway drugs

Key Informational Sample Deliverables

• Evaluation on new pain drug concept:
• Acceptance
• Likes and Dislikes
• Message recall
• Relevancy to current pain treatment
• Believability
• Uniqueness
• Credibility
• Improvement
• Future intention to prescribe

27 IMS Health Confidential

 Content

• Background and Objectives

• Approach and Methodology
• Project Team
• Timeline and Investment

28 IMS Health Confidential

 The project team consists of experienced market researchers, supported
by the General Manager

• Keep agency updated to internal

business issue to ensure the relevancy
with research objective

• In-charge of leading and delivering the

PRINCIPAL IN CHARGE
project
• Resolve any issues / queries that may
Jowel Tacata- Principal
arise
• Take decisions on next steps

LOCAL ADVISORY

ENGAGEMENT LEADERSHIP • Manage day-to-day project management

Wiwy Sasongko
• Ensure milestones, timelines and project
IMS Indonesia General Manager
Dilla Noverita - Sr. Consultant objectives are met
• Senior level advisors to the project • Resolve issues / queries
• Advises on methodology
• Provides contextual market insights at
analysis stage

PROJECT MANAGEMENT
• Manage and facilitate on-going project
Ryo Sudibyo - Consultant queries and client needs

29
 Wiwy Sasongko
General Manager, IMS Indonesia

Wiwy Sasongko leads Commercial Effectiveness Services (CES) in Indonesia which

includes Primary Market Research, Sales Force Effectiveness and Training.

Prior to joining IMS, Wiwy was a Director with Nielsen Indonesia, leading its market
research and analytic consulting team. Wiwy advised his clients in market assessment,
performance monitoring, new product launch, forecasting, pricing, marketing mix,
distribution and assortment. Prior to that, Wiwy was in Nielsen US.

Before joining Nielsen, Wiwy was a consultant with ZS Associates in the US. Wiwy advised
clients in sales force size and structure, segmentation and targeting, and call planning.

Wiwy graduated from RMIT University in Australia majoring in Manufacturing Engineering

and held a master’s degree in Industrial Engineering from Purdue University in the US.

30
 Jowel Tacata
Principal, IMS Indonesia
Jowel Tacata is currently Principal in IMS Indonesia . Within IMS, Jowel has worked for
several years in different markets such as Korea and ASEAN in various commercial roles,
including consulting on commercial effectiveness projects .

Jowel has been based in Indonesia over the last 5 years, and has also worked with PT
Novartis Pharma and PT APL-Zuellig in areas of SFE, business development , alliance and
partnering.

Jowel has also more than a decade of corporate experience in the Philippine
pharmaceutical industry, assumed various key positions in sales and marketing in different
multinational companies such as AstraZeneca, Abbott , Astellas and Quintiles.

Jowel holds a Bachelor of Arts degree in Political Science from University of the Philippines
(UP), Diliman and an MBA from University of Santo Tomas.

31
 Dilla Noverita
Sr. Consultant, IMS Indonesia
Prior to joining IMS, Dilla was a Senior Research Manager at The Nielsen Company of Indonesia, in the
Consumer Insights Division.

Before joining Nielsen, Dilla was employed in Synovate Indonesia. Dilla has been a qualitative
researcher for about seven years and have great experience in conducting FGD, IDI, Consumer
Immersion and Ethnography. Her sector specialties are lies within FMCG, Telecommunication, Banking,
Healthcare (Ethical and non Ethical), Agriculture, Banking and Consumer Electronics.

Dilla has rich across conventional qualitative research tools like FGD, IDI as also in consumer
Ethnography and cognitive interviewing, across urban and rural audiences. Apart from that, she also has
great experience in integration marketing research such as combined study of quantitative and
qualitative both for consumers and shoppers, combined study of retail audit and qualitative, also combine
study of analytics and qualitative studies

She has been involved in consumer experience mapping study, segmentation and consumers profiling,
brand health study, Ads-check, product concept development and home-tested study.

Dilla has a Master Degree, Faculty of Business, Monash University, Melbourne-Australia. She was a
Lecturer cum Researcher at Trisakti University School of Management. She wrote and presented
scientific papers on various business topics. Her articles and journals have been published by national
education institutions such as Gajah Mada University, and University of Indonesia.

32
 Ryo Sudibyo
Consultant, IMS Indonesia
Prior joining IMS Health, Ryo has worked at PT Rifan Financindo as Business Consultant,
and The Nielsen Company as Quantitative Research Project Management and most
recently at PT Kadence International as Quantitative Sr. Project Management.

Ryo has 3 years of market research experience. With Kadence he was responsible
handling several pharmaceutical projects, FMCG and banking projects and was
responsible for quantitative project and the analysis of field work process.

He has been involved in many quantitative project types such as brand health study, usage
and awareness, Ads-check, product concept development, product test, and BHUT (Brand
Home Use Test).

Ryo finished his Bachelor Degree in Industrial Engineer at Universitas Katolik

Parahyangan.

33
 Content

• Background and Objectives

• Approach and Methodology
• Project Team
• Timeline and Investment

34 IMS Health Confidential

 Timeline – Stage 1 study will take around 7 weeks until final report

Month 1 Month 2
Phase Project
1 2 3 4 1 2 3 4

Kick-Off meeting

Setting Up

IMS database analysis

Recruitment , DG development/improvement, Setting-Up for
FGDs
Fieldwork Mini FGDs and Phone Interview
Data Gathering
Analysis and Reporting

35 IMS Health Confidential

 Timeline – Stage 2 study will take around 10 weeks until final report

Month 1 Month 2 Month 3

Phase Project
1 2 3 4 1 2 3 4

Synthesis Discussion and Workshop

Setting Up

Questionnaire Development and Approval

Face-to-Face (F2F) Interview, N=150, JKT & SBY
Data Gathering and Tabulation
Analysis and Reporting

36 IMS Health Confidential

 Investment - Estimation
Stage Method Cost

Stage 1 – Market Method: IMS Database Analysis and Mini-FGDs with KOLs IDR 200,000,000
Definition, Size and
Competition 5 FGDs with each Anesthetic, Neurologist, Ortho-Surgeon, Onco-Surgeon and
Internist

Deliverable: All will be up-to-Reporting and FGD facilities cost will be considered as
Pass-through Cost
Cost for 1 FGD with KOL - Reporting only IDR 8,000,000
Cost for 1 FGD with KOLs – Recruitment (including incentives for respondents), IDR 40,000,000
Moderation and Reporting (equipped with IMS database analysis)

Stage 2 – Demand Method : IDR 330,000,000

Initiation Exploration (A Quantitative
Product Concept Testing N=150 (each specialist will have N=30)
Study) Type of specialist involved :
Anesthetic, Neurologist, Ortho-Surgeon, Onco-Surgeon and Internist

Deliverable : Up-to Reporting

Option : Qualitative Method - IDI IDR 250,000,000

N=25(each specialist will have N=5)
Type of specialist involved :
Anesthetic, Neurologist, Ortho-Surgeon, Onco-Surgeon and Internist

*)The cost exclude 10% VAT

This cost includes the following:
• Project management, material design, fieldwork cost, incentives, data processing and analysis, report writing, and presentation of result

37 IMS Health Confidential

38